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Abstract 
 
Background: 
This meta-analysis examined the impact of preoperative corticosteroids on interleukin 6 (IL-
6), C-reactive protein (CRP), and complications following surgery for gastrointestinal cancer. 
 
Methods: 
A systematic review was performed using appropriate keywords.  Random-effects meta-
analysis was performed.  
 
Results: 
11 RCTs with 474 patients, were included.  Corticosteroids were significantly associated with 
lower IL-6 on postoperative day 1 (mean difference -148 pg/mL, 95% CI -205 to -92, 
p<0.001), 2 (-33 pg/mL, 95% CI -58 to -8, p=0.01), and 3 (-31 pg/mL, 95% CI -52 to -11, 
p=0.002), lower CRP on day 3 (-45 mg/L, 95% CI -68 to -21, p<0.001), and 7 (-14 mg/L, 
95% CI -27 to -1, p=0.04), and fewer postoperative infective complications (OR 0.47, 95% 
CI 0.26 to 0.83, p=0.01).  
 
Conclusion: 
Corticosteroids were associated with reduction in the postoperative systemic inflammatory 
response and complications following surgery for gastrointestinal cancer.  
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1. Introduction 
Surgery leads to a predictable metabolic, neuroendocrine and immunological response [1-2].  
Activation of the sympathetic nervous system leads to the release of catecholamines which 
induce tachycardia, hypertension and tachypnoea [3].  The cellular response to surgical 
trauma involves the production of pro-inflammatory cytokines including tumour necrosis 
factor (TNF) alpha, interleukin (IL) 1, IL-6, and IL-8 [4-5].   Such cytokines act to mobilise 
the innate immune system, resulting in the activation of neutrophils, macrophages and 
platelets, causing fever and contributing to nausea.  Circulating pro-inflammatory cytokines 
also act on hepatocytes, altering the synthesis of the acute phase proteins, such as C-reactive 
protein (CRP), albumin, fibrinogen and constituents of the complement cascade [6].   
Postoperative IL-6 and CRP concentrations in particular, have been found to be useful 
markers of the magnitude of the surgical injury [7]. The magnitude of this postoperative 
systemic inflammatory response, and in particular the routinely available CRP, is associated 
with the development of complications following colorectal surgery, oesophagectomy and 
liver resection [8-10].  Furthermore, threshold concentrations of CRP have been established, 
in the postoperative period, (190 mg/L on postoperative day 2, 170mg/L on postoperative day 
3 and 145 mg/L on postoperative day 4), which predict the likelihood of developing or not 
developing infective complications and anastomotic leak [11-12].   
The magnitude of this postoperative systemic inflammatory response and its 
relationship with postoperative complications is of particular interest in the context of surgery 
for gastrointestinal cancers.  Previous studies have demonstrated an association between 
postoperative complications, particularly infective complications, and poorer long-term and 
oncologic outcomes following surgery for gastrointestinal cancer [13-14].  Indeed, it has been 
suggested that the magnitude of the postoperative systemic inflammatory response should 
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prompt further investigation to exclude the development of a postoperative infective 
complication [15].  Furthermore, the upcoming PRECious trial (NCT02102217) aims to 
randomize patients to early CT imaging or standard postoperative care if CRP rises above 
140mg/L on postoperative day 3 to 5 following abdominal surgery [16].   
Given the relationship between the magnitude of the postoperative systemic 
inflammatory response, the development of postoperative complications, and long-term 
outcomes, there is increasing interest in the attenuation of this postoperative stress response.  
Preoperative corticosteroids are a logical choice of intervention given their potential potency 
and duration of effect [17-18].  Indeed, preoperative corticosteroids have been used as they 
have been found to reduce postoperative nausea and vomiting and analgesic requirements 
following abdominal surgery [19-20].  A recent meta-analysis reported that preoperative 
corticosteroids significantly reduced postoperative day one IL-6, postoperative complications, 
infective complications, and length of stay following abdominal surgery [21].  Preoperative 
corticosteroids have also been reported to reduce postoperative IL-6 and complication rates 
following liver resection and oesophagectomy in meta-analyses of small numbers of studies 
[22-24].  To our knowledge, no prior meta-analysis has investigated comprehensively the 
impact of preoperative corticosteroids on the postoperative surgical stress response following 
surgery for gastrointestinal cancer.  The present meta-analysis is the first to examine their 
impact on CRP.  Both IL-6 and CRP are objective measures of the magnitude of the systemic 
inflammatory response to surgery, however CRP is more readily available in the clinical 
setting [7].  Furthermore, no meta-analysis has attempted to assess the dose response between 
preoperative corticosteroids and the magnitude of the postoperative systemic inflammatory 
response and postoperative complication rate. 
Therefore the objective of the present systematic review and meta-analysis was to 
examine the impact of preoperative corticosteroids compared to placebo in the context of 
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randomized controlled trials, on the surgical stress response, in particular postoperative IL 6 
and CRP, and their relationship with the development of infective complications, following 
surgery for gastrointestinal cancers.  
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2. Methods 
The present systematic review and meta-analysis was performed and reported in accordance 
with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
statement (Supplementary Digital Content 1 – PRISMA Checklist.docx) [25].  
 
2.1 Outcomes of interest: 
The primary outcome of interest was the impact of single dose preoperative 
corticosteroids on markers of the postoperative stress response following surgery for 
gastrointestinal cancer, in particular IL-6 and CRP.  Those studies reporting chronic 
preoperative corticosteroid use or dosing at other perioperative time points were excluded.  
Secondary outcomes included the impact of preoperative corticosteroids on postoperative 
complications, infective complications, and anastomotic leak following surgery for 
gastrointestinal cancer, including pre-specified subgroup analysis based on surgical 
speciality/site.  Postoperative complications were coded as categorised by the authors of the 
included studies where possible.  Where there was doubt the authors of the present study 
categorised complications using a schemata described previously [26].  Post hoc meta-
regression of the impact of corticosteroid dose on postoperative day 1 IL-6 was performed 
following completion of the pre-specified analyses.  Study selection and data extraction was 
performed by one author (SM) and any uncertainties resolved by consensus discussion with 
the senior authors (PH, DM). 
 
 
 
10 
 
2.2 Literature search and study selection: 
A systematic literature review was performed of the US National Library of Medicine 
(MEDLINE), PubMed, and the Cochrane Database of Systematic Reviews (CDSR) from 
inception to March 2015 inclusive.  Subsequent to several pilot search strategies the 
following search term was used, “(cancer OR malignan* OR tumour OR tumor OR 
neoplasm*) AND (steroid OR corticosteroid OR glucocorticoid OR methylpredniso* OR 
predniso* OR dexamethasone) AND (surgery OR operati* OR perioperati* OR preoperati*) 
along with the Cochrane Highly Sensitive Search Strategy for RCTs [26].  Abstracts were 
screened for relevance and those studies which were animal and pre-clinical, those studies not 
published in English, and review articles were excluded.  Relevant full text articles were then 
appraised.  Randomized controlled trials of single dose preoperative corticosteroids in 
surgery for gastrointestinal cancer which reported on a marker of the postoperative systemic 
inflammatory response and postoperative complications were included in the review.  
Reference lists of included studies were hand searched for further relevant studies. 
 
2.3 Data extraction and meta-analysis: 
Data from included studies was extracted to tables and analysis was performed using 
Review Manager version 5.3 (RevMan 5.3, The Nordic Cochrane Centre, The Cochrane 
Collaboration, Copenhagen, Denmark).  Meta-analysis of the impact of corticosteroids on 
postoperative IL 6 and CRP was performed by calculating the mean difference and 95% 
confidence intervals (CI) using the inverse variance method and combining study outcomes 
using a random effects model.  Where data other than means and standard deviations were 
reported an attempt was made to calculate these values using published confidence intervals 
or p values as described by Hozo and colleagues or by the Cochrane Handbook for 
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Systematic Reviews of Interventions [27-28].  Results of the meta-analysis of the impact of 
corticosteroids on infective complications was assessed by odds ratios and 95% CIs using the 
Mantel-Haenzsel method and combining study outcomes using a random effects model.  Peto 
odds ratios and their 95% CIs were combined using a fixed effects model to determine the 
impact of preoperative corticosteroids on anastomotic leak as there were a small number of 
events.  Meta-regression, using a random effects model, was performed with respect to the 
impact of corticosteroid dose on postoperative day 1 IL-6, following conversion to 
hydrocortisone equivalents using a freely available Macro (Wilson, D. B. (Version 
2005.05.23). Meta-analysis macros for SAS, SPSS, and Stata. Retrieved, 7th May 2015 from 
http://mason.gmu.edu/~dwilsonb/ma.html) with IBM SPSS version 22 for Windows 
(Chicago, IL, USA) [28].  Two tailed p values <0.05 were considered statistically significant.           
 
2.4 Assessment of bias: 
Assessment of the risk of bias was carried out using the Cochrane Collaboration tool 
provided by Review Manager version 5.3 (RevMan 5.3, The Nordic Cochrane Centre, The 
Cochrane Collaboration, Copenhagen, Denmark).  Data was assessed for heterogeneity using 
the I2 statistic and χ2 test interpreted using the guidance from the Cochrane Handbook for 
Systematic Reviews of Interventions [27].  Assessment of potential publication bias was 
carried out by visual inspection of funnel plots.  P values ≤0.05 were considered statistically 
significant.   
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3. Results 
 
3.1 Study selection process: 
The study selection process is summarised in Figure 1.  Using the search protocol 
described, 2,428 abstracts were identified.  At screening, 2,354 abstracts were excluded, of 
which 16 were animal or pre-clinical studies, 227 were not in the English language, 328 were 
review articles, 3 were duplicate publications and 1,780 were not relevant to the review.  Full 
text articles were reviewed of the remaining 74 studies.   
After assessment of full text articles 63 studies were excluded, of which 36 were not 
in gastrointestinal surgery patients, 6 did not include patients with malginancy, 14 did not 
include the intervention of interest or included corticosteroids at timings other than 
preoperatively, 3 did not measure either postoperative IL-6 or CRP, 2 used historical controls, 
1 was a duplicate study, and 1 a co-intervention of epidural analgesia alongside preoperative 
corticosteroids.  The remaining 11 randomised controlled trials including 474  patients were 
included in the review (Table 1) [30-40].   
Of the included studies, 3 including 139 patients were in colorectal surgery [38-40], 4 
including 156 patients were in oesophageal surgery [30, 32, 34-35], and 4  including 179 
patients were in hepatic surgery [31, 33, 36-37].  Of the 474  included patients, 436  ( 92%) 
had surgery for gastrointestinal cancer while 38 (8%) from 6 studies had surgery for benign 
gastrointestinal disease but were included in the meta-analysis [31, 36-38, 40].  All included 
patients underwent open surgery, no studies of minimally invasive surgery suitable for 
inclusion were returned by the search strategy. 
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3.2 Validity assessment: 
The risk of study bias is summarised using the RevMan 5.3 Risk of bias summary tool 
(Supplemental Digital Content 2 – Risk of bias summary.pdf).  Most studies were at low risk 
of bias however 3  did not report outcomes for patients who dropped out following 
randomisation [33, 36, 38], and 6  did not adequately report allocation concealment and 
blinding [30-31, 33-36]. 
 
3.3 Impact of preoperative corticosteroids on IL-6: 
Of the included studies, 10 including  422 patients reported the impact of preoperative 
corticosteroids on postoperative IL-6 following surgery for gastrointestinal cancer and were 
included in meta-anaysis (Figure 2) [30-38, 40].  Preoperative corticosteroids were 
significantly associated with lower serum concentrations of IL-6 following surgery for 
gastrointestinal cancer on postoperative day 1 (p<0.001), day 2 (p=0.01), and day 3 
(p=0.002), but not postoperative day 5 (p=0.11)  or day 7 (p=0.69).  There was a wide 
variation in heterogeneity between studies with the greatest on postoperative day 1 (I2=86%, 
p<0.001) and the least on postoperative day 7 (I2=6%, p=0.36). 
 
3.4 Impact of preoperative corticosteroids on C-reactive protein: 
Of the included studies, 6 including 206 patients reported the impact of preoperative 
corticosteroids on postoperative CRP following surgery for gastrointestinal cancer and were 
included in meta-anaysis (Figure 3) [31, 35, 37-40].  Preoperative corticosteroids were 
significantly associated with lower serum concentrations of CRP following surgery for 
gastrointestinal cancer on postoperative day 3 (p<0.001), and day 7 (p=0.04), but not 
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postoperative day 1 (p=0.09) or day 2 (p=0.11).  There was a wide variation in heterogeneity 
between studies with the greatest on postoperative day 2 (I2=87%, p<0.001) and the least on 
postoperative day 7 (I2=0%, p=0.44). 
 
3.5 Impact of preoperative corticosteroid dose on postoperative IL-6 and CRP 
Within the 10 studies reporting postoperative day 1 IL-6, there was a wide variation in 
preoperative corticosteroid dose in the intervention arm [30-38, 40].  Following dose 
conversion to hydrocortisone equivalents (HEs) of both dexamethasone (1mg =  30 HEs) and 
methylprednisolone (1mg = 5 HEs) [29], it was found that 2 studies gave patients 240 HEs 
[37,39], 3 studies gave 2,500 HEs [31, 35, 36], 3 studies gave 3,500 HEs [30, 32, 34], and 2 
studies gave 10,500 HEs preoperatively [33, 37].  Meta-regression revealed no significant 
relationship between the corticosteroid dose as measured by HEs and effect size on 
postoperative day 1 IL-6 (B = -0.0065, 95% CI -0.029 to 0.016, p=0.569).  No further meta-
regression of the impact of preoperative corticosteroid dose on postoperative IL-6 or CRP 
effect size was performed as the number of studies precluded meaningful analysis. 
 
3.6 Impact of preoperative corticosteroids on all postoperative complications 
Of the included studies 10, including 434 patients with 163 complications, reported 
the impact of preoperative corticosteroids on postoperative complications following surgery 
for gastrointestinal cancer and were included in meta-analysis (Figure 4) [30-34, 36-40].  
Preoperative corticosteroids were significantly associated with fewer postoperative 
complications following surgery for gastrointestinal cancer (OR 0.44, 95% CI 0.28 to 0.70, 
p<0.001) There was minimal heterogeneity between studies (I2=2%, p=0.42).  At subgroup 
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analysis, preoperative corticosteroids were significantly associated with fewer postoperative 
complications following surgery for oesophageal ( p=0.01) and liver (p=0.02) but not 
colorectal malignancy (p=0.25).   
 
3.7 Impact of preoperative corticosteroids on postoperative infective complications: 
Of the included studies 9, including 388 patients with 68 infective complications, 
reported the impact of preoperative corticosteroids on postoperative infective complications 
following surgery for gastrointestinal cancer and were included in meta-analysis (Figure 5) 
[31-32, 34-40].  Preoperative corticosteroids were significantly associated with fewer 
postoperative infective complications following surgery for gastrointestinal cancer (OR 0.47, 
95% CI 0.26 to 0.83, p=0.01).  There was minimal heterogeneity between studies (I2=0%, 
p=0.54).  At subgroup analysis, preoperative corticosteroids were significantly associated 
with fewer postoperative infective complications following surgery for liver malignancy 
(p=0.02) but not colorectal (p=0.15) or oesophageal malignancy (p=0.58).   
 
3.8 Impact of preoperative corticosteroids on anastomotic leak: 
Of the included studies 7, including 295 patients and 19 events, reported the impact of 
preoperative corticosteroids on anastomotic leak following colorectal or oesophageal surgery 
for cancer and were included in meta-analysis (Figure 6) [30, 32, 34-35, 38-40].  The 
remaining 5 studies were in hepatic surgery thus did not report anastomotic leak.  There was 
no significant association between preoperative corticosteroids and anastomotic leak (OR 
1.13, 95% CI 0.44 to 2.90, p=0.79).  There was minimal heterogeneity between studies 
(I2=0%, p=0.61).  At subgroup analysis there was no association between preoperative 
16 
 
corticosteroids and anastomotic leak following surgery for either colorectal (p=0.71) or 
oesophageal malignancy (p=1.00).   
 
3.9 Assessment of publication bias: 
Visual assessment of a funnel plot of studies reporting the impact of preoperative 
corticosteroids on postoperative CRP and all complications following surgery for 
gastrointestinal cancer (Figure 7) suggests that there may be evidence of publication bias with 
a positive skew amongst smaller studies. 
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4. Discussion 
The present systematic review and meta-analysis reports that preoperative corticosteroids 
reduce the magnitude of the systemic inflammatory response, in particular IL-6 and CRP, and 
are significantly associated with fewer postoperative infective complications following 
surgery for gastrointestinal cancer.   
The results of the present study with regard to postoperative IL-6 are consistent with 
recent meta-analyses of randomized controlled trials of preoperative corticosteroids in 
colorectal surgery, liver surgery and esophagectomy [21-24, 41].  In addition, the present 
meta-analysis reports a significant reduction in IL-6 on postoperative days 2, 3 and 5 in those 
patients given preoperative corticosteroids.    The present study reports a significant reduction 
in CRP on postoperative days 3 and 7 in those given preoperative corticosteroids however 
found no significant impact of preoperative corticosteroids on postoperative day 1 or 2.  As 
CRP is usually seen to reach its peak concentration around 48 hours after the initial surgical 
insult it may be that comparison on postoperative day 1 and 2 does not accurately reflect the 
influence of preoperative corticosteroids on the postoperative systemic inflammatory 
response [6].  It is of interest that even within the control groups of the studies included in the 
present meta-analysis, the mean data were below postoperative CRP thresholds associated 
with the development of postoperative complications.  For example, it has recently been 
advocated that simple objective postoperative CRP thresholds >150mg/l on post-operative 
days 3-5 be used to alert clinicians to the risk of post-operative complications before clinical 
signs and symptoms [42]. Moreover, when examined in detail by operative site, the mean 
CRP concentrations reported by the studies included in the present meta-analysis were 
significantly lower than values reported in a comprehensive systematic review of the timing 
and peak magnitude of postoperative IL-6 and CRP following elective colorectal, 
oesophageal and liver surgery [7].  Therefore, it may be that patients recruited to previous 
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randomised controlled trials of preoperative corticosteroids had a lower systemic 
inflammatory response compared with unselected patients.  If this were to be the case then 
this may have implications for the randomised trials that reported efficacy of  pre-operative 
corticosteroids on complication rates.  In particular, it may be that the efficacy was 
underestimated. 
 As with previous meta-analyses there was a wide variation in corticosteroid dose 
equivalence and timing [43].  The degree of heterogeneity between studies within each 
speciality in the present meta-analysis suggests that this does have an impact on the degree of 
attenuation of the postoperative systemic inflammatory response.  Within the present meta-
analysis, no significant association was found between varying corticosteroid dose 
equivalencies and postoperative day 1 IL-6 effect size between studies.  However, this 
analysis was performed on a post hoc basis in response to data heterogeneity.  In addition, 
dose timing and the differing half-life of dexamethasone and methylprednisolone were not 
considered and may be implicated [43].  The results of the present study do not define the 
ideal dose of preoperative corticosteroid to moderate the systemic inflammatory response or 
postoperative nausea and vomiting.  For example, a recent meta-analysis of preoperative 
corticosteroids in the prevention of postoperative nausea and vomiting reported similar 
efficacy with lower doses of IV dexamethasone (4-5mg), when compared to higher doses (8-
10mg) [44].  However, the efficacy of preoperative corticosteroids will depend on a number 
of factors including the magnitude of the systemic inflammatory response (eg. preventing 
patients breaching established threshold values of CRP) and the route and frequency of dose 
(eg. large single dose or smaller multiple doses).  Further work, in the context of randomised 
trials examining varying corticosteroid doses with reference  the magnitude of the post-
operative systemic inflammatory response, is therefore required. 
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Postoperative IL-6 and CRP concentrations have been reported to be markers of the 
magnitude of the postoperative stress response [7].  In relation to short term postoperative 
morbidity, several recent meta-analyses have demonstrated the utility of elevated 
postoperative serum CRP in the early diagnosis of infective complications and anastomotic 
leak in gastrointestinal surgery [10, 12, 15].  In addition, the magnitude of the postoperative 
CRP has been reported to be associated with complication severity following colorectal 
surgery  [45-46].  Although this inflammatory response may represent an epiphenomenon 
rather than a cause of infective complications, given that the presence of a systemic 
inflammatory response (as evidenced by IL-6 or CRP) [7] is primarily an upregulated innate 
immune response (with  consequent suppression of adaptive immunity), it  is plausible that 
the magnitude of the postoperative systemic inflammatory response plays a role in the 
development of postoperative infective complications [47].  Indeed, the results of the present 
review are consistent with such a causal relationship.  However, further interventional studies 
of preoperative corticosteroids would be required to prove such a relationship. 
It is known that corticosteroids alter gene transcription and thus protein synthesis 
following intracellular receptor binding, however the exact mechanism by which they act to 
reduce inflammation is poorly understood [48].  Glucocorticoids act on the innate immune 
system including myeloid tissue, inhibiting the activity of neutrophils and macrophages via 
reduced transcription of several proinflammatory cytokines, and by increasing the 
transcription of lipocortins which themselves inhibit cyclo-oxygenase dependent 
inflammation pathways [49].  They are also recognised to have a down regulatory effect on 
adaptive immunity and lymphoid tissue, probably via inhibition of nuclear factor κB (NF- 
κB) [50].  The results of the present review taken with that of previous meta-analyses suggest 
that, in the postoperative period, the action of corticosteroid may at least be partly due to 
reduced transcription and production of IL-6 by innate immune cells, consequently reduced 
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synthesis of CRP by hepatocytes [21, 23-24].  Although both IL-6 and CRP are objective 
markers of the postoperative stress response and have both been associated with the 
development of complications following gastrointestinal surgery, CRP is routinely available 
in clinical practice [7].  Indeed, in a recent review of risk factors associated with anastomotic 
leak following colorectal surgery the authors advocate routine measurement of CRP on 
postoperative days 3 to 5, with a concentration greater than 150mg/L prompting the 
investigation of potentially developing complications [42].  In addition, other studies have 
investigated the use of other markers associated with the development of postoperative 
complications, for example procalcitonin, however the IMACORS study reported that CRP 
was more accurate in the detection of postoperative infective complications following 
colorectal surgery [51].  Furthermore, it has long been recognised that albumin is also a 
marker of the postoperative stress response [6], and is associated with postoperative 
complications and mortality [52].  It remains to be determined whether albumin, in terms of 
predicting post-operative complication, offers prognostic value in addition to that of CRP and 
whether albumin may be a useful therapeutic target for pre-operative corticosteroids. 
 
There has long been a concern regarding the inhibitory effect of corticosteroids on 
collagen formation leading to postoperative wound dehiscence and potentially anastomotic 
leak.  However, the present meta-analysis along with prior randomised trials and meta-
analyses have failed to demonstrate a significant increase in either complication in patients 
given corticosteroids [21, 24, 53-54].  Much of the prior evidence regarding wound healing 
and infection has arisen from literature surrounding surgery for inflammatory bowel disease, 
in those undergoing transplant surgery, or in those with diseases of the hypothalamo-
pituitary-adrenal axis [55].  Indeed, recent meta-analysis of both experimental and clinical 
trials suggests that receiving corticosteroids at standard therapeutic doses for 10 days or less 
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is unlikely to impair wound healing [56].  Lastly, as recent preliminary reports suggest that 
preoperative corticosteroids may have a detrimental impact on oncologic outcome, some 
consideration should be given to their impact on longer term outcomes, especially in surgery 
for gastrointestinal cancer [57-58]. 
The main limitation of the present systematic review and meta-analysis is the 
relatively small number of patients included.  To maximise the number of patients within the 
analysis several gastrointestinal surgical specialities were considered together using a random 
effects model.  In addition there were a small number of patients included within the present 
meta-analysis who had undergone surgery for benign gastrointestinal disease.  Indeed these 
factors, to an extent, limit the generalisability of the results of the present study.  However, 
the exclusion of the 6 studies which included a small proportion of patients without malignant 
disease would have significantly reduced the power of the present meta-analysis [30, 35-37, 
39].  A significant degree of heterogeneity was reported in the analysis of postoperative IL-6 
and CRP.  This may reflect the pooling of the various surgical specialities.  However, no 
study individually reported a statistically significant increase in either postoperative IL-6 or 
CRP in the corticosteroid treatment group.  Thus, although there are likely to be differences 
in the studied patient groups or methodology, the direction of the treatment effect at least, is 
very likely to be similar across the included studies.  There was a wide variability in 
concentrations of IL 6 and CRP amongst studies within the same postoperative day.  Both the 
biological variability of IL 6 and CRP, alongside the variety of surgical specialties included 
in the present study may account for this [59].  Other potential confounders include the use of 
a variety of preoperative corticosteroids, their dose and timing, although a random effects 
model was used as an attempt to minimise this, alongside meta-regression techniques.   In 
addition, there may be a degree of publication bias toward positive results amongst the 
smaller studies included in the meta-analysis.   In the present study, despite a broad and 
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inclusive search strategy, there were no trials conducted in the USA included in the analysis.  
Therefore, it would appear that although preoperative corticosteroids are used in routine 
clinical practice in the USA, no formal RCTs have been undertaken there.  Finally, all of 
those studies included in the present meta-analysis were published prior to 2009.  A single 
study in liver surgery, published in 2010, was excluded due to the use of postoperative 
corticosteroids in the treatment group, however it interestingly reported reduced 
concentrations of IL-6 and CRP in the treatment group with a trend toward fewer 
complications [60].  The lack of more recent studies may relate to the rapid uptake of 
enhanced recovery or fast-track postoperative protocols in gastrointestinal surgery which 
often include preoperative corticosteroids for the prevention of postoperative nausea and 
vomiting  [61].  Nevertheless, the results of the present review with regard to the effect of 
preoperative corticosteroids on IL-6 and CRP provide important new information since they 
suggest that the efficacy of such interventions may be dependent on the magnitude of the 
postoperative systemic inflammatory response. 
The results of the present systematic review and meta-analysis suggest that 
preoperative corticosteroids are associated with a reduction in the magnitude of the 
postoperative stress response and , within some subgroups, the likelihood of postoperative 
complications following surgery for gastrointestinal cancer.  Although the magnitude of this 
postoperative systemic inflammatory response, especially CRP, has been associated with the 
development of complications following surgery, relatively few studies, have examined 
whether the attenuation of the systemic inflammatory response with preoperative 
corticosteroids may indeed reduce infective complication rates.    Clearly, given the 
significant heterogeneity in the small number of studies included in the present meta-analysis, 
further work is warranted. 
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7. Tables and footnotes 
7.1 Table 1: Clinical trials investigating the impact of preoperative steroids on the postoperative stress response following surgery for 
gastrointestinal cancer 
Author Year Journal Country n Speciality Steroid/dose/route
/timing 
Surgical stress 
response  
Period Significant outcomes 
Kirdak et al. 2008 Am Surg Turkey 27 Colorectal Dexamethasone 8mg IV 
at induction 
Pain, nausea, IL 6, CRP POD 1-3 None 
Zargar-
Shoshtari et al.  
2009 Br J Surg New 
Zealand 
60 Colorectal Dexamethasone 8mg 
IV, at induction 
Pain, nausea, WCC, 
Neutrophils, CRP, IL 1β, 
IL 6, IL 8, IL 10, IL 13, 
TNFα, (serum and 
peritoneal cytokines), 
fatigue 
Pain and nausea  POD 
1-3, Fatigue POD 1-
60, CRP and 
cytokines POD 1 
Higher WCC,  neutrophils 
and lower pain, nausea, 
serum IL 6, serum IL 8, 
peritoneal IL 6, peritoneal 
IL 13 in steroid group 
Vignali et al. 2009 Dis Colon 
Rectum 
Italy 52 Colorectal Methylprednisolone 
30mg/kg IV, 60 mins 
preop 
Pain, FVC, FEV1, CRP, 
IL 6, IL 8, TNFα  
POD 1-5 Higher FVC, FEV1 and 
lower pain, CRP, IL 6, IL 8 
in steroid group 
Matsutani et al. 1998 J Surg Res Japan 33 Oesophageal Methylprednisolone 
10mg/kg at induction 
TNFα, IL 6, PT, APTT, 
AT III 
POD 1-7 Higher AT III and lower 
TNFα, IL 6 in steroid group 
Sato et al. 2002 Ann Surg Japan 66 Oesophageal Methylprednisolone 
10mg/kg at induction 
IL 1, IL 6, IL 8, IL 10, 
cortisol, lymphocytes, 
neutrophils 
POD 1-7 Higher IL 10 and lower IL 
1, IL 6, and IL 8 in steroid 
group 
Takeda et al.  2003 J Nippon 
Med Sch 
Japan 17 Oesophageal Methylprednisolone 
10mg/kg IV at 
induction 
Serum and 
broncheoalveolar IL 6 and 
IL 8 
POD 1 Lower serum IL 6 and IL 8, 
and lower broncheoalveolar 
IL 8 in steroid group 
Yano et al.  2005 Hepatogas
troenterol
Japan 40 Oesophageal Methylprednisolone 
500mg IV 2hrs preop 
IL 6, IL 8, IL 10, WCC, 
rectal pHi, body weight 
POD 1-3 Lower IL 6, IL 8 and CRP 
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ogy 
Yamashita et al. 2001 Arch Surg Japan 33 Liver Methylprednisolone 
500mg IV 2hrs preop 
IL 6, IL 10, CRP, Bil, 
AST, ALT 
POD 1-7 Higher IL 10 and lower Bil, 
IL 6, CRP in steroid group 
Muratore et al. 2003 Br J Surg Italy 53 Liver Methylprednisolone 
30mg/kg IV at 
induction 
IL 6, Bil, AST, ALT, PT POD 1 Lower IL 6 in steroid group 
Aldrighetti et 
al. 
2006 Liver 
Transpl 
Italy 73 Liver Methylprednisolone 
500mg IV at induction 
IL 6, TNFα, Bil, AST, 
ALT, PT, platelets, AT 
III, D-dimer 
POD 1-5 Higher AT III, platelets, and 
lower IL 6, TNFα in steroid 
group 
Schmidt et al. 2007 J 
Hepatobili
ary 
Pancreat 
Surgery 
Germany 20 Liver Methylprednisolone 
30mg/kg IV 90 mins 
preop 
IL 6, IL 8, IL 10, CRP, 
TNFα, HLA-DR, Bil 
 Lower IL 6, IL 8, CRP, 
TNFα, Bil in steroid group 
POD postoperative day,  IV intravenous,  IL interleukin, CRP C-reactive protein, TNF tumour necrosis factor, WCC white cell count, FVC forced vital capacity, FEV forced 
expiratory volume, ADH anti-diuretic hormone, AT antithrombin, Bil bilirubin, AST aspartate transaminase, ALT alanine transaminase, PT prothrombin time, HLA human 
leukocyte antigen 
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8. Figures and Legends 
8.1 Figure 1:  PRISMA flowchart demonstrating study selection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Studies indentified 
by search strategy 
(n = 2,428) 
Abstracts excluded at screening:  (n = 2,354) 
Pre-clinical study (n  = 16) 
Non-English (n = 227) 
Review article (n  = 328) 
Duplicate (n = 3) 
Non-relevant (n = 1,780) 
Full text reviewed for 
relevance 
(n = 74) 
Excluded:  (n = 63) 
 
Not gastrointestinal (n = 36) 
Benign gastrointestinal (n = 6) 
No perioperative only steroid (n = 14) 
No outcome of interest (n = 3) 
Historical controls (n = 2) 
Co-intervention (n = 1) 
Duplicate (n=1) 
Studies included 
(n = 11) 
Colorectal (n = 3) 
Oesophageal (n = 4) 
Hepatic (n = 4) 
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8.2 Figure 2: Impact of preoperative corticosteroids on serum interleukin 6 following surgery 
for gastrointestinal cancer 
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Subtotal (95% CI)
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8.3 Figure 3: Impact of preoperative corticosteroids on serum C-reactive protein following 
surgery for gastrointestinal cancer 
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8.4 Figure 4: Impact of preoperative corticosteroids on all postoperative complications 
following surgery for gastrointestinal cancer 
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8.5 Figure 5: Impact of preoperative corticosteroids on infective postoperative complications 
following surgery for gastrointestinal cancer 
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8.6 Figure 6: Impact of preoperative corticosteroids on anastomotic leak following surgery 
for gastrointestinal cancer 
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8.7 Figure 7: Funnel plots of the impact of preoperative corticosteroids on A: postoperative 
C-reactive protein and B: all postoperative complications following surgery for 
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Risk of bias in individual 
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12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
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Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
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Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  12-16and 
(Fig 3-5) 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  13 and 
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Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
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